Scientist.com Expands Tumor Model Finder with XenoSTART’s Highly Relevant, Patient-Derived Tumor Models
This partnership significantly increases global access to XenoSTART’s high-demand tumor models.
Scientist.com, the leading R&D procurement orchestration platform for the life sciences, today announced a major expansion of its Tumor Model Finder (TMF) following a strategic partnership with XenoSTART, a global leader in patient-derived xenograft (PDX) model development and testing. The addition of hundreds of unique and high-demand XenoSTART models pushes the TMF past a milestone of 10,000 searchable oncology models, giving cancer researchers unprecedented access to diverse and clinically relevant tools.
“Pharma discovery teams often face critical delays accessing translational research partners with deeply characterized PDX models that accurately reflect real-world patient disease complexity,” said Michael J. Wick, PhD, Chief Scientific Officer at XenoSTART. “By joining the Scientist.com marketplace, XenoSTART eliminates this significant barrier, providing immediate access to our highly relevant, patient-derived tumor models that are directly linked to our global clinical network. This integration empowers drug developers to confidently accelerate therapeutic decision-making and precisely guide their translational strategies—ultimately speeding effective cancer treatments to patients.”
Scientist.com's Tumor Model Finder is a centralized, AI-powered platform that aggregates and standardizes tumor model data from 20+ leading CROs. It allows researchers to search, compare, and source PDX, CDX, organoid, and cell line models—spanning 17 cancer types—through a single workflow. The platform also includes drug response profiles, genomic alterations (e.g., KRAS, BRAF mutations), and RNA seq-based gene expression data to support informed model selection and study design.
“XenoSTART’s contribution significantly boosts the depth and quality of our TMF offerings,” said Javier Pineda, PhD, Director of Preclinical AI at Scientist.com. “Researchers can now find models with richer data and greater relevance to their specific cancer studies.”
This collaboration also highlights the translational impact of START’s global research ecosystem. With patient-derived tissue samples sourced from START’s expansive oncology trial network, XenoSTART’s models provide critical continuity between preclinical evaluation and clinical trial execution—helping pharmaceutical companies make faster, more confident decisions in oncology drug development.
To learn more or schedule a demo of the Tumor Model Finder, email diseasemodels@scientist.com.
About Scientist.com
Scientist.com is the life-science industry’s premier AI-powered marketplace and procurement-orchestration platform. Founded in 2007 and headquartered in Solana Beach, California, the company simplifies every stage of drug discovery and development by unifying supplier search, competitive bidding, contracting, compliance and analytics in a single, secure workspace. More than 20 of the world’s top 30 pharma companies, 100+ biotech organizations and the US National Institutes of Health rely on Scientist.com to access a vetted network of 6,000+ specialized providers, shorten cycle times and reduce costs while meeting the highest ethical and regulatory standards. Visit Scientist.com to discover how we accelerate science.
About XenoSTART
Founded in 2007, XenoSTART is a translational research organization dedicated to advancing oncology drug development through clinically relevant preclinical cancer models. The XenoSTART Patient-Derived Xenograft (XPDX) platform features more than 2,800 models across a broad range of tumor types and disease stages sourced from patients treated at START’s domestic and international cancer centers. Models are deeply characterized using histologic analysis, DNA/RNA sequencing, and in vivo drug sensitivity testing, and are clinically annotated with the donor patient’s treatment history and clinical outcome. By bridging real-world tumor biology with rigorous preclinical science, XenoSTART enables pharmaceutical partners to make smarter, faster decisions from bench to bedside. Learn more about XenoSTART at https://startresearch.com/preclinical/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250723028694/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S.23.7.2025 22:51:00 CEST | Press release
ANZUPGO® (delgocitinib) cream now becomes the first and only FDA-approved treatment specifically approved for the treatment of adults living with moderate-to-severe chronic hand eczema (CHE) in the U.S.1 CHE affects approximately one in ten adults worldwide, yet previously, there has been no specific treatment FDA-approved for those living with the disease.2,3 The approval represents an important milestone for LEO Pharma’s expanding presence in the U.S. as it broadens its portfolio of dermatology treatments to address unmet needs. LEO Pharma, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream (20 mg/g) for the topical treatment of moderate-to-severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable.1 ANZUPGO is an innovative steroid-free, topical pan-Janus kinase (JAK) inhibitor for adults with CHE.1 ANZUPGO inh
Laserfiche Named a Leader in Nucleus Research Content Services and Collaboration Value Matrix 202523.7.2025 20:00:00 CEST | Press release
Laserfiche is a Leader for the 10th consecutive year, ranks highest in usability. Laserfiche — the leading SaaS provider of intelligent content management and business process automation — is a Leader in the Nucleus Research Technology Value Matrix for Content Services and Collaboration for the 10th year in a row. Among the vendors evaluated, Laserfiche ranks highest overall in usability. Download a copy of the report here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250723109668/en/ Laserfiche is a Leader for the 10th consecutive year. “As a leader in this year’s Value Matrix, Laserfiche was rated highest in usability for its AI productivity tools, new administration hub, process automation and integration capabilities,” said Evelyn McMullen, research manager at Nucleus Research and author of the report. CSC as a Strategic Advantage: AI-powered Information Management Recently released Laserfiche AI-powered features are a
Multiply Group Completes Acquisition of Tendam, Doubling Operational EBITDA and Expanding Global Footprint23.7.2025 19:53:00 CEST | Press release
Tendam is Spain's second-largest apparel group by market share and one of Europe’s leading omnichannel apparel groups. Tendam’s 12 well-established owned fashion brands offer diversity and international exposure, further deepening the Group’s presence in consumer-focused industries. The transaction, valued at AED 5.6 billion (€ 1.3 billion) enterprise value, positions Multiply Group as a key player in the global Retail & Apparel landscape. Multiply Group (ADX: MULTIPLY), the Abu Dhabi-based investment holding company that invests in and operates businesses globally, today completed its first major investment in Europe with the acquisition of a majority stake in Tendam, Spain’s second-largest apparel group by market share1. The deal doubles Multiply’s operational EBITDA post-consolidation and expands its model to acquire standout businesses, unlock potential through capital and tech, and deliver sustained market leadership. This press release features multimedia. View the full release h
General Aviation Community Unites to Support the 2026 Special Olympics Airlift23.7.2025 17:11:00 CEST | Press release
During the industry’s iconic Experimental Aircraft Association (EAA) AirVenture event in Oshkosh, Wisconsin, leading general aviation organizations — including EAA and General Aviation Manufacturers Association (GAMA) — announced their collective support and endorsement of the 2026 Special Olympics Airlift event. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250723984082/en/ Ron Draper, president and CEO, Textron Aviation and Jack J. Pelton, chairman and CEO, Experimental Aircraft Association celebrate the general aviation community uniting to support the 2026 Special Olympics Airlift during the industry’s iconic Experimental Aircraft Association (EAA) AirVenture event in Oshkosh, Wisconsin. (Photo: Textron Aviation) The Special Olympics Airlift, organized by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, mobilizes hundreds of volunteer Cessna, Beechcraft and Hawker pilots and aircraft to create the world’s larg
The University of Melbourne Selects Rimini Street to Reduce Risk and Accelerate Innovation Around its Oracle Systems23.7.2025 15:00:00 CEST | Press release
Top ranked Australian university selects Rimini Support™, Rimini Protect™ and Rimini Connect™ for its Oracle systems to focus IT resources towards strategic initiatives that deliver exceptional student experiences Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced that the top-ranking higher learning institute in Australia, The University of Melbourne, has engaged Rimini Street to enable greater digital innovation investments for its organization consisting of 55,000 students and 10,000 staff. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250723436719/en/ The University of Melbourne Selects Rimini Street to Reduce Risk and Accelerate Innovation Around its Oracle Systems By selecting Rimini Support™, Rimini Connect™ and Rimini Protect™ for its Ora
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom